Centre for Medical Genetics, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Belgium.
Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.
Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):46-62. doi: 10.55563/clinexprheumatol/kzkq6y. Epub 2022 May 18.
The vast majority of reported (likely) pathogenic missense variants in the genes coding for the fibrillar collagens leads to the substitution of one of the obligatory glycine residues in the Gly-Xaa-Yaa repeat sequence of the triple helical domain. Their phenotypic consequences and deleterious effects have been well-documented. However, with increasing access to molecular diagnostic testing based on next-generation sequencing techniques, such as sequencing of multi-gene panels and whole-exome sequencing, non-glycine substitutions are more frequently identified in individuals suspected to have a heritable collagen disorder, but their pathogenic effect is often difficult to predict.Some specific non-glycine substitutions in the proα1(I)- (p.(Arg312Cys)) and proα1(III)- (glutamic acid to lysine at different positions) collagen chain have been identified in a number of individuals presenting a phenotype showing features of both classical and vascular Ehlers-Danlos syndrome. The number of reported individuals with these defects is currently very low, and several of these non-glycine substitutions had initially been categorised as variants of unknown significance (VUS), complicating early diagnosis, accurate counselling, management guidelines, and correct classification. This collaborative study reports on the phenotype of 22 and 7 individuals harbouring these rare variants in COL1A1 and COL3A1, respectively, expanding our knowledge on clinical presentation, phenotypic variability, and natural history, and informing on the risk for potentially life-threatening events, such as vascular, gastro-intestinal, and pregnancy-related complications.
绝大多数编码纤维胶原的基因中报道的(可能)致病性错义变异导致三螺旋结构域甘氨酸-X-氨基酸-Y 重复序列中必需甘氨酸残基的取代。其表型后果和有害影响已有充分记录。然而,随着基于下一代测序技术(如多基因panel 测序和全外显子组测序)的分子诊断测试的广泛应用,在疑似遗传性胶原病的个体中,越来越多地发现非甘氨酸取代,但它们的致病性效应往往难以预测。一些特定的非甘氨酸取代在脯氨酸α1(I)-(p.(精氨酸 312 为半胱氨酸))和脯氨酸α1(III)-(在不同位置谷氨酸至赖氨酸)胶原链中已经在许多表现出经典型和血管型 Ehlers-Danlos 综合征特征的个体中被识别。目前,报告有这些缺陷的个体数量非常少,其中一些非甘氨酸取代最初被归类为意义不明的变异(VUS),这使得早期诊断、准确咨询、管理指南和正确分类变得复杂。这项合作研究报告了分别在 COL1A1 和 COL3A1 中携带这些罕见变异的 22 名和 7 名个体的表型,扩展了我们对临床表型、表型变异性和自然病史的认识,并为潜在危及生命的事件(如血管、胃肠道和与妊娠相关的并发症)的风险提供了信息。